Studies on the mechanism of action of benzamide riboside

A novel inhibitor of IMP dehydrogenase

Kamran Gharehbaghi, Werner Grünberger, Hiremagalur N. Jayaram

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Benzamide is a well known inhibitor of poly(ADP-ribose)polymerase, an enzyme involved in DNA repair. However, benzamide exhibited neuotoxicity in animals and hence, in the hope of overcoming this problem, benzamide riboside (BR) was synthesized. Our mechanism of action studies on BR suggested that the agent was being metabolized to its 5′-monophosphate and then to its NAD analogue (BAD, benzamide adenine dinucleotide) that inhibits Inosine 5′-monophosphate dehydrogenase (IMPDH). IMPDH is the rate-limiting enzyme of the branched purine nucleotide synthetic pathway that provides guanylates including GTP and dGTP. There are two isoforms of IMPDH, type I that is constitutively present in all cells, and type II that is inducible and is present in highly proliferating cells such as cancer. Ongoing studies with BR analogues suggest that they are more selective in inhibiting IMPDH type II. Our studies have characterized the metabolites of BR, especially its NAD analogue, BAD, by synthesizing this active metabolite by enzymatic means, and identifying its structure by NMR and mass spectrometry. We have partially purified IMPDH from tumor cells and have examined the kinetics of inhibition of IMPDH by BAD. We have also compared biochemical and cytotoxic activities of BR with tiazofurin and selenazofurin, that share similar mechanisms of action with BR. Our studies demonstrated that 2-3 fold more BAD is formed compared to TAD and SAD, the active metabolites of tiazofurin and selenazofurin, respectively. BR has demonstrated potent cytotoxic activity in a diverse group of human tumor cells, specifically more active in sarcomas and CNS neoplasms compared to tiazofurin or selenazofurin. Future in vivo animal studies should set a stage for determining its effectiveness in clinical Phase I studies.

Original languageEnglish (US)
Pages (from-to)743-748
Number of pages6
JournalCurrent Medicinal Chemistry
Volume9
Issue number7
StatePublished - 2002
Externally publishedYes

Fingerprint

IMP Dehydrogenase
tiazofurin
Adenine
Metabolites
NAD
Tumors
Neoplasms
Animals
Cells
Purine Nucleotides
Enzymes
Guanosine Triphosphate
3-(1-deoxyribofuranosyl)benzamide
DNA Repair
Sarcoma
Mass spectrometry
benzamide
Mass Spectrometry
Protein Isoforms
Repair

Keywords

  • Benzamide riboside
  • Biochemical and cytotoxic activity
  • IMP dehydrogenase

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Studies on the mechanism of action of benzamide riboside : A novel inhibitor of IMP dehydrogenase. / Gharehbaghi, Kamran; Grünberger, Werner; Jayaram, Hiremagalur N.

In: Current Medicinal Chemistry, Vol. 9, No. 7, 2002, p. 743-748.

Research output: Contribution to journalArticle

Gharehbaghi, K, Grünberger, W & Jayaram, HN 2002, 'Studies on the mechanism of action of benzamide riboside: A novel inhibitor of IMP dehydrogenase', Current Medicinal Chemistry, vol. 9, no. 7, pp. 743-748.
Gharehbaghi, Kamran ; Grünberger, Werner ; Jayaram, Hiremagalur N. / Studies on the mechanism of action of benzamide riboside : A novel inhibitor of IMP dehydrogenase. In: Current Medicinal Chemistry. 2002 ; Vol. 9, No. 7. pp. 743-748.
@article{dfd172ad290248c59128c13ec84cb03b,
title = "Studies on the mechanism of action of benzamide riboside: A novel inhibitor of IMP dehydrogenase",
abstract = "Benzamide is a well known inhibitor of poly(ADP-ribose)polymerase, an enzyme involved in DNA repair. However, benzamide exhibited neuotoxicity in animals and hence, in the hope of overcoming this problem, benzamide riboside (BR) was synthesized. Our mechanism of action studies on BR suggested that the agent was being metabolized to its 5′-monophosphate and then to its NAD analogue (BAD, benzamide adenine dinucleotide) that inhibits Inosine 5′-monophosphate dehydrogenase (IMPDH). IMPDH is the rate-limiting enzyme of the branched purine nucleotide synthetic pathway that provides guanylates including GTP and dGTP. There are two isoforms of IMPDH, type I that is constitutively present in all cells, and type II that is inducible and is present in highly proliferating cells such as cancer. Ongoing studies with BR analogues suggest that they are more selective in inhibiting IMPDH type II. Our studies have characterized the metabolites of BR, especially its NAD analogue, BAD, by synthesizing this active metabolite by enzymatic means, and identifying its structure by NMR and mass spectrometry. We have partially purified IMPDH from tumor cells and have examined the kinetics of inhibition of IMPDH by BAD. We have also compared biochemical and cytotoxic activities of BR with tiazofurin and selenazofurin, that share similar mechanisms of action with BR. Our studies demonstrated that 2-3 fold more BAD is formed compared to TAD and SAD, the active metabolites of tiazofurin and selenazofurin, respectively. BR has demonstrated potent cytotoxic activity in a diverse group of human tumor cells, specifically more active in sarcomas and CNS neoplasms compared to tiazofurin or selenazofurin. Future in vivo animal studies should set a stage for determining its effectiveness in clinical Phase I studies.",
keywords = "Benzamide riboside, Biochemical and cytotoxic activity, IMP dehydrogenase",
author = "Kamran Gharehbaghi and Werner Gr{\"u}nberger and Jayaram, {Hiremagalur N.}",
year = "2002",
language = "English (US)",
volume = "9",
pages = "743--748",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Studies on the mechanism of action of benzamide riboside

T2 - A novel inhibitor of IMP dehydrogenase

AU - Gharehbaghi, Kamran

AU - Grünberger, Werner

AU - Jayaram, Hiremagalur N.

PY - 2002

Y1 - 2002

N2 - Benzamide is a well known inhibitor of poly(ADP-ribose)polymerase, an enzyme involved in DNA repair. However, benzamide exhibited neuotoxicity in animals and hence, in the hope of overcoming this problem, benzamide riboside (BR) was synthesized. Our mechanism of action studies on BR suggested that the agent was being metabolized to its 5′-monophosphate and then to its NAD analogue (BAD, benzamide adenine dinucleotide) that inhibits Inosine 5′-monophosphate dehydrogenase (IMPDH). IMPDH is the rate-limiting enzyme of the branched purine nucleotide synthetic pathway that provides guanylates including GTP and dGTP. There are two isoforms of IMPDH, type I that is constitutively present in all cells, and type II that is inducible and is present in highly proliferating cells such as cancer. Ongoing studies with BR analogues suggest that they are more selective in inhibiting IMPDH type II. Our studies have characterized the metabolites of BR, especially its NAD analogue, BAD, by synthesizing this active metabolite by enzymatic means, and identifying its structure by NMR and mass spectrometry. We have partially purified IMPDH from tumor cells and have examined the kinetics of inhibition of IMPDH by BAD. We have also compared biochemical and cytotoxic activities of BR with tiazofurin and selenazofurin, that share similar mechanisms of action with BR. Our studies demonstrated that 2-3 fold more BAD is formed compared to TAD and SAD, the active metabolites of tiazofurin and selenazofurin, respectively. BR has demonstrated potent cytotoxic activity in a diverse group of human tumor cells, specifically more active in sarcomas and CNS neoplasms compared to tiazofurin or selenazofurin. Future in vivo animal studies should set a stage for determining its effectiveness in clinical Phase I studies.

AB - Benzamide is a well known inhibitor of poly(ADP-ribose)polymerase, an enzyme involved in DNA repair. However, benzamide exhibited neuotoxicity in animals and hence, in the hope of overcoming this problem, benzamide riboside (BR) was synthesized. Our mechanism of action studies on BR suggested that the agent was being metabolized to its 5′-monophosphate and then to its NAD analogue (BAD, benzamide adenine dinucleotide) that inhibits Inosine 5′-monophosphate dehydrogenase (IMPDH). IMPDH is the rate-limiting enzyme of the branched purine nucleotide synthetic pathway that provides guanylates including GTP and dGTP. There are two isoforms of IMPDH, type I that is constitutively present in all cells, and type II that is inducible and is present in highly proliferating cells such as cancer. Ongoing studies with BR analogues suggest that they are more selective in inhibiting IMPDH type II. Our studies have characterized the metabolites of BR, especially its NAD analogue, BAD, by synthesizing this active metabolite by enzymatic means, and identifying its structure by NMR and mass spectrometry. We have partially purified IMPDH from tumor cells and have examined the kinetics of inhibition of IMPDH by BAD. We have also compared biochemical and cytotoxic activities of BR with tiazofurin and selenazofurin, that share similar mechanisms of action with BR. Our studies demonstrated that 2-3 fold more BAD is formed compared to TAD and SAD, the active metabolites of tiazofurin and selenazofurin, respectively. BR has demonstrated potent cytotoxic activity in a diverse group of human tumor cells, specifically more active in sarcomas and CNS neoplasms compared to tiazofurin or selenazofurin. Future in vivo animal studies should set a stage for determining its effectiveness in clinical Phase I studies.

KW - Benzamide riboside

KW - Biochemical and cytotoxic activity

KW - IMP dehydrogenase

UR - http://www.scopus.com/inward/record.url?scp=0036249542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036249542&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 743

EP - 748

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 7

ER -